Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Transcripts
  • inderesTV
  • Portfolio
  • Forum
  • Q&A
  • About Us
    • Our Coverage
    • Team

Philip Coombes

Equity Research Analyst

Philip Coombes portrait

Coverage

TrygSkjern BankDanske BankNorth MediaFøroya BankiD/S NordenSparekassen Sjælland-FynAsetekNTG Nordic Transport GroupBooztSKAKOMT Højgaard HoldingSP GroupHafniaFlügger GroupRoblonAscelia PharmaXplora TechnologiesRTXVestjysk BankNetcompany GroupErriaGrønlandsbankenTormDFDSCurasightBioPortoGubraGabriel Holding

Latest content

ShowingAll content types

SP Group (One-pager): Consolidation restarts with Ide-Pro acquisition

Research 2026-01-05 12:30 by Philip Coombes, Rasmus Køjborg
SP Group

Curasight (One-pager): Entering Clinical Validation of a uPAR Theranostic Platform

Research 2025-12-22 12:36 by Philip Coombes, Michael Friis
Curasight

WindowMaster: 2026 guidance points to back on track

Research 2025-12-17 15:00 by Michael Friis, Philip Coombes
WindowMaster International

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account

Gubra - New partnership with Camurus to develop a long-acting treatment for hypoparathyroidism

Analyst Comment 2025-12-16 13:53 by Philip Coombes
Gubra

Flügger Q2'2025/26 - Profitable rebound intact despite export market restructuring

Research 2025-12-15 08:25 by Philip Coombes
Flügger Group

Flügger Q2'25/26 preview: Gradual growth and margin expansion to continue with positive fx impacts

Analyst Comment 2025-12-11 15:48 by Philip Coombes
Flügger Group

Hafnia Q3 2025 - Solid results in line with consensus driven by tighter vessel supply

Analyst Comment 2025-12-01 08:49 by Philip Coombes
Hafnia

SP Group (One-pager): Confirms 2025 guidance despite a challenging Q3 2025

Research 2025-11-20 11:57 by Philip Coombes, Rasmus Køjborg
SP Group

Gabriel Holding Q4’24-25 preview: Positioning for continued execution in 2025/26e

Analyst Comment 2025-11-18 16:41 by Philip Coombes
Gabriel Holding

ExpreS2ion - Licensing agreement with SIIPL highlights platform value

Analyst Comment 2025-11-12 15:27 by Philip Coombes
ExpreS2ion Biotech Holding
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.